Abstract
Surv Anesthesiol 2016;60(2):79–80 Although oral thrombin inhibitor dabigatran is associated with less bleeding risks than vitamin K antagonists, there are still high-risk anticoagulant effects that, without a reversal antidote, can be life threatening. Agents that have been used to attempt reversal of these effects, such as nonactivated prothrombin complex concentrates (PCCs) and recombinant factor VIIa (FVIIa), have had no clinical trial validating their effectiveness in restoring hemostasis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
